Nucor earnings beat by $0.08, revenue fell short of estimates
NATICK, Mass. - Patients using the Allurion Program maintained approximately 95% of their weight loss one year after the gastric balloon passed out of their body, according to new research published by Allurion Technologies, Inc. (NYSE:ALUR), a medical device company currently valued at $23.8 million. According to InvestingPro data, the company maintains impressive gross profit margins of 66.4%, though it faces significant operational challenges.
The first study, conducted across nine international obesity centers with 522 patients, showed an average weight reduction of 14.4kg (32lbs) or 13.9% of total body weight during the four-month balloon treatment period. One year after balloon passage, patients maintained an average weight loss of 13.9kg (31lbs) or 13.2% of total body weight. Despite these promising clinical results, InvestingPro analysis indicates the company is experiencing rapid cash burn, with analysts not expecting profitability this year.
A second study involving 497 patients at a single center between January 2020 and January 2024 demonstrated similar results, with patients losing an average of 14.3% of total body weight during the four-month treatment period. In this study, 86% of patients maintained their weight loss one year later.
The Allurion Program features a swallowable gastric balloon that requires no endoscopy or anesthesia for placement, combined with the company’s Virtual Care Suite that includes a mobile app for patients and digital tools for healthcare providers.
"Two of the key tenets of metabolically healthy weight loss are losing weight and keeping it off," said Dr. Shantanu Gaur, Founder and CEO of Allurion, in the press release statement.
The Allurion Gastric Balloon remains an investigational device in the United States, though it is available in other markets globally.
These findings come from two separate studies published in Obesity Surgery and the Journal of Laparoendoscopic & Advanced Surgical Techniques, respectively.
In other recent news, Allurion Technologies reported a significant decline in revenue for Q1 2025, with earnings dropping to $5.6 million compared to $9.4 million in the same period last year. Despite this decrease, the company managed to improve its gross margin to 75% from 73% and reduced its adjusted loss from operations by 48%. Additionally, Allurion announced the submission of the final module of its Pre-Market Approval application to the FDA for its swallowable gastric balloon weight loss device. The company’s AUDACITY Study met its pre-specified co-primary endpoints, although the second endpoint initially did not achieve the required margin. In another development, Allurion entered a strategic distribution partnership with Minogue Medical Inc. to expand its weight loss program in Canada. This partnership will utilize Minogue Medical’s extensive network in the Canadian healthcare system. These recent developments reflect Allurion’s ongoing efforts to strengthen its market position and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.